GILD
Companies
NASDAQ
Gilead Sciences, Inc.
Health Care
$108.02
+$16.97 (+18.64%)
Price Chart
Overview
About GILD
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Market Cap
$80.6B
Volume
701.0M
Avg. Volume
754.0M
P/E Ratio
13.91
Dividend Yield
4.70%
Employees
17.5K
Company Information
Latest News for GILD
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
June 5, 2025
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
June 18, 2025
Final Trade: NVO, CELH, LION, GILD
June 9, 2025
Should You Buy Gilead Stock At $110?
June 18, 2025
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
June 19, 2025
Risk & Correlation Analysis
Market Correlation
0.21
Low Correlation
Volatility
Medium (0.29)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, GILD shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$80.6B
Volume701.0M
P/E Ratio13.91
Dividend Yield4.70%
Important Dates
Next Dividend
Next Earnings
August 1, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025